New injector tested for arthritis drug in healthy volunteers

NCT ID NCT07007091

Completed Knowledge-focused Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested how well risankizumab enters the body when given through an on-body injector compared to a standard prefilled syringe. 260 healthy volunteers received the drug by one of the two methods. Researchers measured drug levels in the blood and checked for side effects to see if the injector works as well as the syringe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Risankizumab
What this could lead to: If successful, this could lead to a more convenient way to give risankizumab using an on-body injector instead of a syringe.
What could go wrong: This is an early-phase study in healthy people, not patients. It only checks how the drug moves through the body and basic safety, not whether it works for any disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS

Contacts and locations

Locations

Acpru /Id# 276043

Grayslake, Illinois, 60030, United States
Cpmi /Id# 276490

Miami, Florida, 33172, United States
PPD Phase I Clinic /ID# 276525

Austin, Texas, 78744, United States
Ppd - Las Vegas Research Unit /ID# 276565

Las Vegas, Nevada, 89113, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.